{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T20:15:31Z","timestamp":1792700131928,"version":"4.5.0"},"reference-count":119,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,2]],"date-time":"2025-03-02T00:00:00Z","timestamp":1740873600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,2]],"date-time":"2025-03-02T00:00:00Z","timestamp":1740873600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-91875-3","type":"journal-article","created":{"date-parts":[[2025,3,2]],"date-time":"2025-03-02T08:53:24Z","timestamp":1740905604000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Screening of common genomic biomarkers to explore common drugs for the treatment of pancreatic and kidney cancers with type-2 diabetes through bioinformatics analysis"],"prefix":"10.1038","volume":"15","author":[{"given":"Alvira","family":"Ajadee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabkat","family":"Mahmud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnob","family":"Sarkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tasfia","family":"Noor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reaz","family":"Ahmmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md. Nurul","family":"Haque Mollah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,2]]},"reference":[{"key":"91875_CR1","doi-asserted-by":"crossref","unstructured":"Zimmet, P., Alberti, K. G. M. M. & Shaw, J. L20 Diabetes Epidemic. 414. (2001).","DOI":"10.1038\/414782a"},{"key":"91875_CR2","doi-asserted-by":"publisher","unstructured":"Ogurtsova, K. et al. IDF diabetes atlas: global estimates of undiagnosed diabetes in adults for 2021. Diabetes Res. Clin. Pract. 183 https:\/\/doi.org\/10.1016\/j.diabres.2021.109118 (2022).","DOI":"10.1016\/j.diabres.2021.109118"},{"key":"91875_CR3","doi-asserted-by":"publisher","unstructured":"Zhang, P. H. et al. Increased risk of Cancer in patients with type 2 diabetes mellitus: A retrospective cohort study in China. BMC Public. Health. 12 (1). https:\/\/doi.org\/10.1186\/1471-2458-12-567 (2012).","DOI":"10.1186\/1471-2458-12-567"},{"key":"91875_CR4","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.arcmed.2005.01.003","volume":"36","author":"JL Leahy","year":"2005","unstructured":"Leahy, J. L. Pathogenesis of type 2 diabetes mellitus. Arch. Med. Res. 36, 197\u2013209. https:\/\/doi.org\/10.1016\/j.arcmed.2005.01.003 (2005).","journal-title":"Arch. Med. Res."},{"key":"91875_CR5","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1016\/j.juro.2014.06.014","volume":"192","author":"SP Psutka","year":"2014","unstructured":"Psutka, S. P. et al. Diabetes mellitus is independently associated with an increased risk of mortality in patients with clear cell renal cell carcinoma. J. Urol. 192, 1620\u20131627. https:\/\/doi.org\/10.1016\/j.juro.2014.06.014 (2014).","journal-title":"J. Urol."},{"key":"91875_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fonc.2023.1280618","volume":"13","author":"X Cheng","year":"2023","unstructured":"Cheng, X. & Hou, Y. Importance of metabolic and immune profile as a prognostic Indicator in patients with diabetic clear cell renal cell carcinoma. Front. Oncol. 13, 1\u201313. https:\/\/doi.org\/10.3389\/fonc.2023.1280618 (2023).","journal-title":"Front. Oncol."},{"key":"91875_CR7","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.jand.2017.07.005","volume":"118","author":"G Eibl","year":"2018","unstructured":"Eibl, G. et al. Diabetes mellitus and obesity as risk factors for pancreatic Cancer. J. Acad. Nutr. Diet. 118, 555\u2013567. https:\/\/doi.org\/10.1016\/j.jand.2017.07.005 (2018).","journal-title":"J. Acad. Nutr. Diet."},{"key":"91875_CR8","doi-asserted-by":"publisher","unstructured":"Gallo, M. et al. Early prediction of pancreatic Cancer from New-Onset diabetes: an associazione Italiana oncologia medica (AIOM)\/Associazione Medici diabetologi (AMD)\/Societ\u00e0 Italiana endocrinologia (SIE)\/Societ\u00e0 Italiana Farmacologia (SIF) multidisciplinary consensus Pos. ESMO Open. 6 https:\/\/doi.org\/10.1016\/j.esmoop.2021.100155 (2021).","DOI":"10.1016\/j.esmoop.2021.100155"},{"key":"91875_CR9","doi-asserted-by":"crossref","unstructured":"C., P. P. T. L. N. P.; M.S., R.; K., X.; A., A. Pancreatic Cancer triggers diabetes through TGF-\u03b2-Mediated selective depletion of islet \u03b2-Cells. Life Sci. Alliance 3. (2020).","DOI":"10.26508\/lsa.201900573"},{"key":"91875_CR10","first-page":"nopagination","volume":"93","author":"A Vavallo","year":"2014","unstructured":", A. V. et al. Pre-Existing type 2 diabetes mellitus is an independent risk factor for mortality and progression in patients with renal cell carcinoma. Med. (United States). 93, nopagination (2014).","journal-title":"Med. (United States)"},{"key":"91875_CR11","unstructured":"Overview. A.C.S.P.C. Key Statistics for Pancreatic Cancer."},{"key":"91875_CR12","doi-asserted-by":"publisher","unstructured":"Barth, D. A. et al. Current concepts of Non-Coding RNAs in the pathogenesis of Non-Clear cell renal cell carcinoma. Cancers (Basel). 11 https:\/\/doi.org\/10.3390\/cancers11101580 (2019).","DOI":"10.3390\/cancers11101580"},{"key":"91875_CR13","doi-asserted-by":"publisher","unstructured":"Sung, W. W., Ko, P. Y., Chen, W. J., Wang, S. C. & Chen, S. L. Trends in the kidney Cancer Mortality-to-Incidence ratios according to health care expenditures of 56 countries. Sci. Rep. 11 https:\/\/doi.org\/10.1038\/s41598-020-79367-y (2021).","DOI":"10.1038\/s41598-020-79367-y"},{"key":"91875_CR14","first-page":"32","volume":"39","author":"S Bahadoram","year":"2022","unstructured":"Bahadoram, S. et al. Renal cell carcinoma: an overview of the epidemiology, diagnosis, and treatment. G Ital. Di Nefrol. 39, 32\u201347 (2022).","journal-title":"G Ital. Di Nefrol"},{"key":"91875_CR15","doi-asserted-by":"crossref","unstructured":"Rahib, L. et al. Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States (Cancer Research 74 (2913-21)). Cancer Res. 2014, 74, 4006. (2014).","DOI":"10.1158\/0008-5472.CAN-14-0155"},{"key":"91875_CR16","unstructured":"Cancer Facts & Fig.\u00a02024."},{"key":"91875_CR17","doi-asserted-by":"publisher","unstructured":"Tracz, A. F., Szczylik, C., Porta, C. & Czarnecka, A. M. Insulin-like growth Factor-1 signaling in renal cell carcinoma. BMC Cancer. 16 https:\/\/doi.org\/10.1186\/s12885-016-2437-4 (2016).","DOI":"10.1186\/s12885-016-2437-4"},{"key":"91875_CR18","doi-asserted-by":"publisher","unstructured":"Giovannucci, E., Harlan, D. M., Archer, M. C. & Bergenstal, R. M. Diabetes and Cancer: A Consensus Report. 60, 207\u2013221, (2010). https:\/\/doi.org\/10.3322\/caac.20078.Available","DOI":"10.3322\/caac.20078.Available"},{"key":"91875_CR19","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1038\/nrc2536","volume":"8","author":"M Pollak","year":"2008","unstructured":"Pollak, M. Insulin and Insulin-like growth factor signalling in neoplasia. Nat. Rev. Cancer. 8, 915\u2013928. https:\/\/doi.org\/10.1038\/nrc2536 (2008).","journal-title":"Nat. Rev. Cancer"},{"key":"91875_CR20","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1038\/nature01322","volume":"420","author":"LM Coussens","year":"2002","unstructured":"Coussens, L. M. & Werb, Z. Inflammation and Cancer. Nature 420, 860\u2013867. https:\/\/doi.org\/10.1038\/nature01322 (2002).","journal-title":"Nature"},{"key":"91875_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2407-14-814","volume":"14","author":"MT Chan","year":"2014","unstructured":"Chan, M. T. et al. Effects of insulin on human pancreatic Cancer progression modeled in vitro. BMC Cancer. 14, 1\u201312. https:\/\/doi.org\/10.1186\/1471-2407-14-814 (2014).","journal-title":"BMC Cancer"},{"key":"91875_CR22","doi-asserted-by":"publisher","unstructured":"Lucke, T. et al. Disease-Specific medication, Patient-Reported diagnoses and their relation to COPD severity for common comorbidities in COPD. PA698, (2017). https:\/\/doi.org\/10.1183\/1393003.congress-2017.pa698","DOI":"10.1183\/1393003.congress-2017.pa698"},{"key":"91875_CR23","doi-asserted-by":"publisher","unstructured":"Zhang, P., Wang, F., Hu, J. & Sorrentino, R. Label propagation prediction of Drug-Drug interactions based on clinical side effects. Sci. Rep. 5 https:\/\/doi.org\/10.1038\/srep12339 (2015).","DOI":"10.1038\/srep12339"},{"key":"91875_CR24","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s40266-020-00747-0","volume":"37","author":"J Sommer","year":"2020","unstructured":"Sommer, J., Seeling, A. & Rupprecht, H. Adverse drug events in patients with chronic kidney disease associated with multiple drug interactions and polypharmacy. Drugs Aging. 37, 359\u2013372. https:\/\/doi.org\/10.1007\/s40266-020-00747-0 (2020).","journal-title":"Drugs Aging"},{"key":"91875_CR25","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1111\/jgs.14870","volume":"65","author":"SE Merel","year":"2017","unstructured":"Merel, S. E. & Paauw, D. S. Common drug side effects and drug-Drug interactions in elderly adults in primary care. J. Am. Geriatr. Soc. 65, 1578\u20131585. https:\/\/doi.org\/10.1111\/jgs.14870 (2017).","journal-title":"J. Am. Geriatr. Soc."},{"key":"91875_CR26","doi-asserted-by":"publisher","first-page":"106411","DOI":"10.1016\/j.compbiomed.2022.106411","volume":"152","author":"MB Hossen","year":"2023","unstructured":"Hossen, M. B. et al. Robust identification of common genomic biomarkers from multiple gene expression profiles for the prognosis, diagnosis, and therapies of pancreatic Cancer. Comput. Biol. Med. 152, 106411. https:\/\/doi.org\/10.1016\/j.compbiomed.2022.106411 (2023).","journal-title":"Comput. Biol. Med."},{"key":"91875_CR27","doi-asserted-by":"publisher","first-page":"559","DOI":"10.2217\/bmm-2016-0111","volume":"10","author":"HT Chang","year":"2016","unstructured":"Chang, H. T. Biomarker discovery using Dry-Lab technologies and High-Throughput screening. Biomark. Med. 10, 559\u2013561. https:\/\/doi.org\/10.2217\/bmm-2016-0111 (2016).","journal-title":"Biomark. Med."},{"key":"91875_CR28","doi-asserted-by":"publisher","first-page":"e0268967","DOI":"10.1371\/journal.pone.0268967","volume":"17","author":"MS Alam","year":"2022","unstructured":"Alam, M. S. et al. Integrated bioinformatics and statistical approaches to explore molecular biomarkers for breast Cancer diagnosis, prognosis and therapies. PLoS One. 17, e0268967. https:\/\/doi.org\/10.1371\/journal.pone.0268967 (2022).","journal-title":"PLoS One"},{"key":"91875_CR29","doi-asserted-by":"publisher","unstructured":"Mosharaf, M. P., Reza, M. S., Gov, E., Mahumud, R. A. & Mollah, M. N. H. Disclosing Potential Key Genes, Therapeutic Targets and Agents for Non-Small Cell Lung Cancer: Evidence from Integrative Bioinformatics Analysis. Vaccines 10, 771, (2022). https:\/\/doi.org\/10.3390\/vaccines10050771","DOI":"10.3390\/vaccines10050771"},{"key":"91875_CR30","doi-asserted-by":"publisher","unstructured":"Reza, M. S. et al. Metadata analysis to explore hub of the hub-Genes highlighting their functions, pathways and regulators for cervical Cancer diagnosis and therapies. Discov Oncol. 13 https:\/\/doi.org\/10.1007\/s12672-022-00546-6 (2022).","DOI":"10.1007\/s12672-022-00546-6"},{"key":"91875_CR31","doi-asserted-by":"publisher","unstructured":"Islam, M. A. et al. Exploring core genes by comparative transcriptomics analysis for early diagnosis, prognosis, and therapies of colorectal Cancer. Cancers (Basel). 15 https:\/\/doi.org\/10.3390\/cancers15051369 (2023).","DOI":"10.3390\/cancers15051369"},{"key":"91875_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12920-023-01488-w","volume":"16","author":"MA Horaira","year":"2023","unstructured":"Horaira, M. A. et al. Bioinformatics screening of Colorectal-Cancer causing molecular signatures through gene expression profiles to discover therapeutic targets and candidate agents. BMC Med. Genomics. 16, 1\u201324. https:\/\/doi.org\/10.1186\/s12920-023-01488-w (2023).","journal-title":"BMC Med. Genomics"},{"key":"91875_CR33","doi-asserted-by":"publisher","first-page":"e0310843","DOI":"10.1371\/journal.pone.0310843","volume":"19","author":"A Ajadee","year":"2024","unstructured":"Ajadee, A. et al. Screening of differential gene expression patterns through survival analysis for diagnosis, prognosis and therapies of clear cell renal cell carcinoma. PLoS One. 19, e0310843 (2024).","journal-title":"PLoS One"},{"key":"91875_CR34","doi-asserted-by":"publisher","unstructured":"Ahmmed, R. et al. H. Bioinformatics analysis to disclose shared molecular mechanisms between Type-2 diabetes and Clear-Cell Renal-Cell carcinoma, and therapeutic indications. Sci. Rep. 14 https:\/\/doi.org\/10.1038\/s41598-024-69302-w (2024).","DOI":"10.1038\/s41598-024-69302-w"},{"key":"91875_CR35","doi-asserted-by":"publisher","unstructured":"Zhang, J. et al. Identification of key genes associated with the process of hepatitis B inflammation and Cancer transformation by integrated bioinformatics analysis. Front. Genet. 12 https:\/\/doi.org\/10.3389\/fgene.2021.654517 (2021).","DOI":"10.3389\/fgene.2021.654517"},{"key":"91875_CR36","doi-asserted-by":"publisher","unstructured":"Liu, G. M., Zeng, H. D., Zhang, C. Y. & Xu, J. W. Key genes associated with diabetes mellitus and hepatocellular carcinoma. Pathol. Res. Pract. 215 https:\/\/doi.org\/10.1016\/j.prp.2019.152510 (2019).","DOI":"10.1016\/j.prp.2019.152510"},{"key":"91875_CR37","doi-asserted-by":"publisher","unstructured":"Zou, J. et al. Identification of key genes associated with polycystic ovary syndrome (PCOS) and ovarian Cancer using an integrated bioinformatics analysis. J. Ovarian Res. 15 https:\/\/doi.org\/10.1186\/s13048-022-00962-w (2022).","DOI":"10.1186\/s13048-022-00962-w"},{"key":"91875_CR38","doi-asserted-by":"publisher","first-page":"463","DOI":"10.2147\/DMSO.S235011","volume":"13","author":"L Jian","year":"2020","unstructured":"Jian, L. & Yang, G. Identification of key genes involved in diabetic peripheral neuropathy progression and associated with pancreatic Cancer. Diabetes Metab. Syndr. Obes. 13, 463\u2013476. https:\/\/doi.org\/10.2147\/DMSO.S235011 (2020).","journal-title":"Diabetes Metab. Syndr. Obes."},{"key":"91875_CR39","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1038\/ng.2323","volume":"44","author":"S Pe\u00f1a-Llopis","year":"2012","unstructured":"Pe\u00f1a-Llopis, S. et al. BAP1 loss defines a new class of renal cell carcinoma. Nat. Genet. 44, 751\u2013759. https:\/\/doi.org\/10.1038\/ng.2323 (2012).","journal-title":"Nat. Genet."},{"key":"91875_CR40","doi-asserted-by":"publisher","first-page":"e70216","DOI":"10.1371\/journal.pone.0070216","volume":"8","author":"KA Ellsworth","year":"2013","unstructured":"Ellsworth, K. A. et al. Contribution of FKBP5 genetic variation to gemcitabine treatment and survival in pancreatic adenocarcinoma. PLoS One. 8, e70216. https:\/\/doi.org\/10.1371\/journal.pone.0070216 (2013).","journal-title":"PLoS One"},{"key":"91875_CR41","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.molmet.2019.03.004","volume":"24","author":"A Khamis","year":"2019","unstructured":"Khamis, A. et al. Laser capture microdissection of human pancreatic Islets reveals novel EQTLs associated with type 2 diabetes. Mol. Metab. 24, 98\u2013107. https:\/\/doi.org\/10.1016\/j.molmet.2019.03.004 (2019). EhehaltF.Marselli, L.; Distler, M.; Richter, D.; et al.","journal-title":"Mol. Metab."},{"key":"91875_CR42","unstructured":"DRUGBANK. online Advanced Kidney Cancer-DRUGBANK Online."},{"key":"91875_CR43","unstructured":"NIH NIH The Cancer Genome Atlas Program - NCI. Cancer Genome Atlas Progr."},{"key":"91875_CR44","unstructured":"Drugs.com Drugs. Used to Treat Renal Cell Carcinoma-Drugs.Com. Drugs used to treat Ren. Cell Carcinoma."},{"key":"91875_CR45","doi-asserted-by":"publisher","unstructured":"Russo, P. S. T. et al. CEMiTool: A bioconductor package for performing comprehensive modular Co-Expression analyses. BMC Bioinform. 19 https:\/\/doi.org\/10.1186\/s12859-018-2053-1 (2018).","DOI":"10.1186\/s12859-018-2053-1"},{"key":"91875_CR46","doi-asserted-by":"publisher","first-page":"27545","DOI":"10.1038\/s41598-024-79391-2","volume":"14","author":"A Sarker","year":"2024","unstructured":"Sarker, A., Aziz, M. A., Hossen, M. B., Mollah, M. M. H. & Al-Amin; Mollah, M. N. H. Discovery of key molecular signatures for diagnosis and therapies of glioblastoma by combining supervised and unsupervised learning approaches. Sci. Rep. 14, 27545. https:\/\/doi.org\/10.1038\/s41598-024-79391-2 (2024).","journal-title":"Sci. Rep."},{"key":"91875_CR47","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1186\/1471-2105-9-559","volume":"9","author":"S Horvath","year":"2008","unstructured":"Horvath, S. & Langfelder, P. W. G. C. N. A. An R package for weighted correlation network analysis. BMC Bioinform. 9, 559 (2008).","journal-title":"BMC Bioinform."},{"key":"91875_CR48","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1101\/gr.1239303","volume":"13","author":"R Christmas","year":"2003","unstructured":"Christmas, R. et al. Cytoscape: A software environment for integrated models of biomolecular interaction networks. Genome Res. 13, 2498\u20132504 (2003).","journal-title":"Genome Res."},{"key":"91875_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1752-0509-8-S4-S11","volume":"8","author":"CH Chin","year":"2014","unstructured":"Chin, C. H. et al. Identifying hub objects and Sub-Networks from complex interactome. BMC Syst. Biol. 8, 1\u20137. https:\/\/doi.org\/10.1186\/1752-0509-8-S4-S11 (2014).","journal-title":"BMC Syst. Biol."},{"key":"91875_CR50","doi-asserted-by":"publisher","unstructured":"Nogales-Cadenas, R. et al. Interpreting gene lists through enrichment analysis and integration of diverse biological information. Nucleic Acids Res. 37 https:\/\/doi.org\/10.1093\/nar\/gkp416 (2009).","DOI":"10.1093\/nar\/gkp416"},{"key":"91875_CR51","doi-asserted-by":"publisher","unstructured":"Pi\u00f1ero, J. et al. The disgenet knowledge platform for disease genomics: 2019 update. Nucleic Acids Res. 48 https:\/\/doi.org\/10.1093\/nar\/gkz1021 (2020).","DOI":"10.1093\/nar\/gkz1021"},{"key":"91875_CR52","doi-asserted-by":"publisher","first-page":"W556","DOI":"10.1093\/nar\/gkz430","volume":"47","author":"Z Tang","year":"2019","unstructured":"Tang, Z., Kang, B., Li, C., Chen, T. & Zhang, Z. GEPIA2: an enhanced web server for Large-Scale expression profiling and interactive analysis. Nucleic Acids Res. 47, W556\u2013W560. https:\/\/doi.org\/10.1093\/nar\/gkz430 (2019).","journal-title":"Nucleic Acids Res."},{"key":"91875_CR53","doi-asserted-by":"publisher","first-page":"3940","DOI":"10.1093\/bioinformatics\/bti623","volume":"21","author":"T Sing","year":"2005","unstructured":"Sing, T., Sander, O., Beerenwinkel, N. & Lengauer, T. R. O. C. R. Visualizing classifier performance in R. Bioinformatics 21, 3940\u20133941. https:\/\/doi.org\/10.1093\/bioinformatics\/bti623 (2005).","journal-title":"Bioinformatics"},{"key":"91875_CR54","doi-asserted-by":"publisher","unstructured":"Khan, A. et al. JASPAR 2018: update of the Open-Access database of transcription factor binding profiles and its web framework. 46, 260\u2013266, (2018). https:\/\/doi.org\/10.1093\/nar\/gkx1126","DOI":"10.1093\/nar\/gkx1126"},{"key":"91875_CR55","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1261\/rna.2239606","volume":"12","author":"P Sethupathy","year":"2006","unstructured":"Sethupathy, P., Corda, B. & Hatzigeorgiou, A. G. TarBase: A comprehensive database of experimentally supported animal MicroRNA targets. Rna 12, 192\u2013197. https:\/\/doi.org\/10.1261\/rna.2239606 (2006).","journal-title":"Rna"},{"key":"91875_CR56","doi-asserted-by":"publisher","unstructured":"Paul, S. et al. 1;1; 2 Daniel Ramage, 2; Nada Amin, 2; Benno Schwikowski, 1, 5 and Trey Ideker2, 3, 4, 5; \u5c71\u672c\u9686\u4e45; \u8c4a\u7530\u76f4\u5e73; \u6df1\u702c\u5409\u90a6; \u5927\u68ee\u654f\u884c Cytoscape: A Software Environment for Integrated Models. Genome Res. 13, 426, (1971). https:\/\/doi.org\/10.1101\/gr.1239303.metabolite","DOI":"10.1101\/gr.1239303.metabolite"},{"key":"91875_CR57","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/75556","volume":"25","author":"JT Dwight","year":"2000","unstructured":"Dwight3, J. T. et al. Gene ontology: tool for the unification of biology. Nat. Genet. 25, 25 (2000).","journal-title":"Nat. Genet."},{"key":"91875_CR58","doi-asserted-by":"publisher","unstructured":"Garcia-Moreno, A. et al. Functional enrichment analysis of regulatory elements. Biomedicines 10 https:\/\/doi.org\/10.3390\/biomedicines10030590 (2022).","DOI":"10.3390\/biomedicines10030590"},{"key":"91875_CR59","doi-asserted-by":"publisher","first-page":"277","DOI":"10.2217\/epi-2017-0118","volume":"10","author":"V Modhukur","year":"2018","unstructured":"Modhukur, V. et al. MethSurv: A web tool to perform multivariable survival analysis using DNA methylation data. Epigenomics 10, 277\u2013288. https:\/\/doi.org\/10.2217\/epi-2017-0118 (2018).","journal-title":"Epigenomics"},{"key":"91875_CR60","doi-asserted-by":"publisher","first-page":"NA","DOI":"10.1002\/jcc.21334","volume":"31","author":"O Trott","year":"2009","unstructured":"Trott, O., Olson, A. J., AutoDock & Vina Improving the speed and accuracy of Docking with a new scoring function, efficient optimization, and multithreading. J. Comput. Chem. 31, NA\u2013NA. https:\/\/doi.org\/10.1002\/jcc.21334 (2009).","journal-title":"J. Comput. Chem."},{"key":"91875_CR61","doi-asserted-by":"publisher","unstructured":"Berman, H. M. et al. The protein data bank. Acta Crystallogr. Sect. D Biol. Crystallogr. 58 https:\/\/doi.org\/10.1107\/S0907444902003451 (2002).","DOI":"10.1107\/S0907444902003451"},{"key":"91875_CR62","doi-asserted-by":"publisher","first-page":"D439","DOI":"10.1093\/nar\/gkab1061","volume":"50","author":"M Varadi","year":"2022","unstructured":"Varadi, M. et al. AlphaFold protein structure database: massively expanding the structural coverage of protein-Sequence space with High-Accuracy models. Nucleic Acids Res. 50, D439\u2013D444. https:\/\/doi.org\/10.1093\/nar\/gkab1061 (2022).","journal-title":"Nucleic Acids Res."},{"key":"91875_CR63","doi-asserted-by":"publisher","first-page":"D1102","DOI":"10.1093\/nar\/gky1033","volume":"47","author":"S Kim","year":"2019","unstructured":"Kim, S. et al. PubChem 2019 update: improved access to chemical data. Nucleic Acids Res. 47, D1102\u2013D1109. https:\/\/doi.org\/10.1093\/nar\/gky1033 (2019).","journal-title":"Nucleic Acids Res."},{"key":"91875_CR64","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.ddtec.2004.11.007","volume":"1","author":"CA Lipinski","year":"2004","unstructured":"Lipinski, C. A. Lead- and Drug-like compounds: the Rule-of-Five revolution. Drug Discov Today Technol. 1, 337\u2013341. https:\/\/doi.org\/10.1016\/j.ddtec.2004.11.007 (2004).","journal-title":"Drug Discov Today Technol."},{"key":"91875_CR65","doi-asserted-by":"publisher","unstructured":"Daina, A., Michielin, O. & Zoete, V. S. A. D. M. E. A free web tool to evaluate pharmacokinetics, Drug-Likeness and medicinal chemistry friendliness of small molecules. Sci. Rep. 7 https:\/\/doi.org\/10.1038\/srep42717 (2017).","DOI":"10.1038\/srep42717"},{"key":"91875_CR66","doi-asserted-by":"crossref","unstructured":"Pires; Blundell, T. L., Ascher, D. B. & PkCSM Predicting Small-Molecule Pharmacokinetic Properties Using Graph-Based Signatures (Theory- How to Enterpret PkCSM Result). pKCSM 5. (2015).","DOI":"10.1021\/acs.jmedchem.5b00104"},{"key":"91875_CR67","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.2337\/dc17-2518","volume":"41","author":"RE Graff","year":"2018","unstructured":"Graff, R. E. et al. Type 2 diabetes in relation to the risk of renal cell carcinoma among men and women in two large prospective cohort studies. Diabetes Care. 41, 1432\u20131437. https:\/\/doi.org\/10.2337\/dc17-2518 (2018).","journal-title":"Diabetes Care"},{"key":"91875_CR68","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.2337\/dc20-0207","volume":"43","author":"J Cho","year":"2020","unstructured":"Cho, J., Scragg, R. & Petrov, M. S. Postpancreatitis diabetes confers higher risk for pancreatic Cancer than type 2 diabetes: results from a nationwide Cancer registry. Diabetes Care. 43, 2106\u20132112. https:\/\/doi.org\/10.2337\/dc20-0207 (2020).","journal-title":"Diabetes Care"},{"key":"91875_CR69","doi-asserted-by":"publisher","unstructured":"Wang, H. D., Zhong, Z. H., Weng, Y. J., Wei, Z. Z. & Zhang, Y. Q. Degraded sericin significantly regulates blood glucose levels and improves impaired liver function in T2d rats by reducing oxidative stress. Biomolecules 11 https:\/\/doi.org\/10.3390\/biom11081255 (2021).","DOI":"10.3390\/biom11081255"},{"key":"91875_CR70","doi-asserted-by":"publisher","first-page":"8781","DOI":"10.2147\/CMAR.S211363","volume":"11","author":"Z Fan","year":"2019","unstructured":"Fan, Z. et al. The crp\/albumin ratio predicts survival and monitors chemotherapeutic effectiveness in patients with advanced pancreatic Cancer. Cancer Manag Res. 11, 8781\u20138788. https:\/\/doi.org\/10.2147\/CMAR.S211363 (2019).","journal-title":"Cancer Manag Res."},{"key":"91875_CR71","doi-asserted-by":"publisher","first-page":"9133","DOI":"10.3892\/ol.2018.8473","volume":"15","author":"J Wang","year":"2018","unstructured":"Wang, J. et al. Bioinformatics and functional analyses of key genes and pathways in human clear cell renal cell carcinoma. Oncol. Lett. 15, 9133\u20139141. https:\/\/doi.org\/10.3892\/ol.2018.8473 (2018).","journal-title":"Oncol. Lett."},{"key":"91875_CR72","doi-asserted-by":"publisher","unstructured":"Pei, Y., Yin, X. & Liu, X. min; qiang TOP2A Induces Malignant Character of Pancreatic Cancer through Activating \u03b2-Catenin Signaling Pathway. Biochim. Biophys. Acta - Mol. Basis Dis. 1864, 197\u2013207, (2018). https:\/\/doi.org\/10.1016\/j.bbadis.2017.10.019","DOI":"10.1016\/j.bbadis.2017.10.019"},{"key":"91875_CR73","doi-asserted-by":"publisher","unstructured":"Yuan, L. et al. Identification of key genes and pathways in human clear cell renal cell carcinoma (CcRCC) by Co-Expression analysis. 14, (2018). https:\/\/doi.org\/10.7150\/ijbs.23574","DOI":"10.7150\/ijbs.23574"},{"key":"91875_CR74","doi-asserted-by":"publisher","first-page":"4169","DOI":"10.3892\/ol.2018.9179","volume":"16","author":"M Ye","year":"2018","unstructured":"Ye, M. et al. A TOP2A-Derived Cancer panel drives Cancer progression in papillary renal cell carcinoma. Oncol. Lett. 16, 4169\u20134178. https:\/\/doi.org\/10.3892\/ol.2018.9179 (2018).","journal-title":"Oncol. Lett."},{"key":"91875_CR75","doi-asserted-by":"crossref","unstructured":"Vastrad, B. & Vastrad, C. Bioinformatics Analysis of Potential Key Genes and Mechanisms in Type 2 Diabetes Mellitus. bioRxiv 2021.03.28.437386. (2021).","DOI":"10.1101\/2021.03.28.437386"},{"key":"91875_CR76","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.canlet.2006.12.020","volume":"249","author":"MJ Duffy","year":"2007","unstructured":"Duffy, M. J., O\u2019Donovan, N., Brennan, D. J., Gallagher, W. M. & Ryan, B. M. Survivin: A promising tumor biomarker. Cancer Lett. 249, 49\u201360. https:\/\/doi.org\/10.1016\/j.canlet.2006.12.020 (2007).","journal-title":"Cancer Lett."},{"key":"91875_CR77","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1080\/14733400500093379","volume":"5","author":"MA Melisko","year":"2005","unstructured":"Melisko, M. A. Multigene assay to predict recurrence of Tamoxifen-Treated, Node-Negative breast Cancer. Women\u2019s Oncol. Rev. 5, 45\u201347. https:\/\/doi.org\/10.1080\/14733400500093379 (2005).","journal-title":"Women\u2019s Oncol. Rev."},{"key":"91875_CR78","doi-asserted-by":"publisher","first-page":"2602","DOI":"10.1093\/emboj\/21.11.2602","volume":"21","author":"HW Wang","year":"2002","unstructured":"Wang, H. W., Sharp, T. V., Koumi, A., Koentges, G. & Boshoff, C. Characterization of an Anti-Apoptotic glycoprotein encoded by Kaposi\u2019s Sarcoma-Associated herpesvirus which resembles a spliced variant of human survivin. EMBO J. 21, 2602\u20132615. https:\/\/doi.org\/10.1093\/emboj\/21.11.2602 (2002).","journal-title":"EMBO J."},{"key":"91875_CR79","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0041976","volume":"7","author":"X Wu","year":"2012","unstructured":"Wu, X. et al. Survivin is required for Beta-Cell mass expansion in the pancreatic Duct-Ligated mouse model. PLoS One. 7, 1\u201311. https:\/\/doi.org\/10.1371\/journal.pone.0041976 (2012).","journal-title":"PLoS One"},{"key":"91875_CR80","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1007\/s00535-003-1224-6","volume":"38","author":"Y Hinoda","year":"2003","unstructured":"Hinoda, Y. et al. Increased expression of MUC1 in advanced pancreatic Cancer. J. Gastroenterol. 38, 1162\u20131166. https:\/\/doi.org\/10.1007\/s00535-003-1224-6 (2003).","journal-title":"J. Gastroenterol."},{"key":"91875_CR81","unstructured":"Bourdon, E. et al. Ren. Carcinomas 1\u201314. (2024)."},{"key":"91875_CR82","unstructured":"Strawbridge, R. J. & Rona, J. Strawbridge Stockholm 2008. (2008)."},{"key":"91875_CR83","doi-asserted-by":"publisher","unstructured":"Bhutia, Y. D. et al. Differential processing of Let-7a precursors influences RRM2 expression and chemosensitivity in pancreatic cancer: role of LIN-28 and SET oncoprotein. PLoS One. 8 https:\/\/doi.org\/10.1371\/journal.pone.0053436 (2013).","DOI":"10.1371\/journal.pone.0053436"},{"key":"91875_CR84","first-page":"5965","volume":"11","author":"J Szarkowska","year":"2021","unstructured":"Szarkowska, J. et al. Original Article RRM2 gene expression depends on BAF180 subunit of SWISNF chromatin remodeling complex and correlates with abundance of tumor infiltrating lymphocytes in CcRCC. Am. J. Cancer Res. 11, 5965\u20135978 (2021).","journal-title":"Am. J. Cancer Res."},{"key":"91875_CR85","unstructured":"S0888754322001525."},{"key":"91875_CR86","doi-asserted-by":"publisher","first-page":"e933443","DOI":"10.12659\/MSM.933443","volume":"27","author":"L Luo","year":"2021","unstructured":"Luo, L., Zhang, G., Wu, T. & Wu, G. Prognostic value of E2F transcription factor expression in pancreatic adenocarcinoma. Med. Sci. Monit. Int. Med. J. Exp. Clin. Res. 27, e933443. https:\/\/doi.org\/10.12659\/MSM.933443 (2021).","journal-title":"Med. Sci. Monit. Int. Med. J. Exp. Clin. Res."},{"key":"91875_CR87","doi-asserted-by":"publisher","unstructured":"Healthcare Engineering, J. O. & Retracted Comprehensive Analysis of the Expression and Prognosis for E2Fs in Human Clear Cell Renal Cell Carcinoma. J. Healthc. Eng. 2022, 9807439, (2022). https:\/\/doi.org\/10.1155\/2022\/9807439","DOI":"10.1155\/2022\/9807439"},{"key":"91875_CR88","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/jcla.24280","volume":"36","author":"Q Ma","year":"2022","unstructured":"Ma, Q. et al. Long Non-Coding RNA screening and identification of potential biomarkers for type 2 diabetes. J. Clin. Lab. Anal. 36, 1\u201310. https:\/\/doi.org\/10.1002\/jcla.24280 (2022).","journal-title":"J. Clin. Lab. Anal."},{"key":"91875_CR89","doi-asserted-by":"publisher","first-page":"5000","DOI":"10.1158\/1078-0432.CCR-08-0746","volume":"14","author":"AC Mita","year":"2008","unstructured":"Mita, A. C., Mita, M. M., Nawrocki, S. T., Giles, F. J. & Survivin Key regulator of mitosis and apoptosis and novel target for Cancer therapeutics. Clin. Cancer Res. 14, 5000\u20135005. https:\/\/doi.org\/10.1158\/1078-0432.CCR-08-0746 (2008).","journal-title":"Clin. Cancer Res."},{"key":"91875_CR90","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/15476286.2023.2286101","volume":"21","author":"S Al-Yahya","year":"2024","unstructured":"Al-Yahya, S. et al. Post-Transcriptional regulation of BIRC5\/Survivin expression and induction of apoptosis in breast Cancer cells by tristetraprolin. RNA Biol. 21, 1\u201315. https:\/\/doi.org\/10.1080\/15476286.2023.2286101 (2024).","journal-title":"RNA Biol."},{"key":"91875_CR91","doi-asserted-by":"publisher","unstructured":"Chen, W. et al. MUC1: structure, function, and clinic application in epithelial cancers. Int. J. Mol. Sci. 22 https:\/\/doi.org\/10.3390\/ijms22126567 (2021).","DOI":"10.3390\/ijms22126567"},{"key":"91875_CR92","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.molmed.2014.02.007","volume":"20","author":"S Nath","year":"2014","unstructured":"Nath, S. & Mukherjee, P. MUC1: A multifaceted oncoprotein with a key role in Cancer progression. Trends Mol. Med. 20, 332\u2013342. https:\/\/doi.org\/10.1016\/j.molmed.2014.02.007 (2014).","journal-title":"Trends Mol. Med."},{"key":"91875_CR93","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1007\/s10555-021-09991-1","volume":"40","author":"SG Kisling","year":"2021","unstructured":"Kisling, S. G. et al. Implications of Prognosis-Associated genes in pancreatic tumor metastasis: lessons from global studies in bioinformatics. Cancer Metastasis Rev. 40, 721\u2013738. https:\/\/doi.org\/10.1007\/s10555-021-09991-1 (2021).","journal-title":"Cancer Metastasis Rev."},{"key":"91875_CR94","doi-asserted-by":"publisher","first-page":"e0169335","DOI":"10.1371\/journal.pone.0169335","volume":"12","author":"M Youns","year":"2017","unstructured":"Youns, M., Abdel, H. & Hegazy, W. The natural flavonoid Fisetin inhibits cellular proliferation of hepatic, colorectal, and pancreatic Cancer cells through modulation of multiple signaling pathways. PLoS One. 12, e0169335. https:\/\/doi.org\/10.1371\/journal.pone.0169335 (2017).","journal-title":"PLoS One"},{"key":"91875_CR95","doi-asserted-by":"publisher","unstructured":"Wang, H., Guo, M., Wei, H. & Chen, Y. Targeting P53 pathways: mechanisms, structures and advances in therapy. Signal. Transduct. Target. Ther. 1\u201335. https:\/\/doi.org\/10.1038\/s41392-023-01347-1 (2023).","DOI":"10.1038\/s41392-023-01347-1"},{"key":"91875_CR96","unstructured":"Wu, Y. Chromatin Accessibility Shapes Tumor Architecture and Microenvironment in Clear Cell Renal Cell Carcinoma."},{"key":"91875_CR97","doi-asserted-by":"publisher","first-page":"100346","DOI":"10.1016\/j.imu.2020.100346","volume":"19","author":"MA Ullah","year":"2020","unstructured":"Ullah, M. A., Sarkar, B. & Akter, F. Prediction of biomarker signatures and therapeutic agents from blood sample against pancreatic ductal adenocarcinoma (PDAC): A Network-Based study. Inf. Med. Unlocked. 19, 100346. https:\/\/doi.org\/10.1016\/j.imu.2020.100346 (2020).","journal-title":"Inf. Med. Unlocked"},{"key":"91875_CR98","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s11523-014-0335-8","volume":"10","author":"I Peters","year":"2015","unstructured":"Peters, I. et al. Decreased MRNA expression of GATA1 and GATA2 is associated with tumor aggressiveness and poor outcome in clear cell renal cell carcinoma. Target. Oncol. 10, 267\u2013275. https:\/\/doi.org\/10.1007\/s11523-014-0335-8 (2015).","journal-title":"Target. Oncol."},{"key":"91875_CR99","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.gene.2014.04.064","volume":"544","author":"NP Muiya","year":"2014","unstructured":"Muiya, N. P. et al. A study of the role of GATA2 gene polymorphism in coronary artery disease risk traits. Gene 544, 152\u2013158. https:\/\/doi.org\/10.1016\/j.gene.2014.04.064 (2014).","journal-title":"Gene"},{"key":"91875_CR100","doi-asserted-by":"publisher","first-page":"e2952","DOI":"10.1038\/cddis.2017.323","volume":"8","author":"RJ Fu","year":"2017","unstructured":"Fu, R. J. et al. DNMT1-Maintained hypermethylation of Kr\u00fcppel-like factor 5 involves in the progression of clear cell renal cell carcinoma. Cell. Death Dis. 8, e2952. https:\/\/doi.org\/10.1038\/cddis.2017.323 (2017).","journal-title":"Cell. Death Dis."},{"key":"91875_CR101","doi-asserted-by":"publisher","first-page":"595","DOI":"10.15252\/embj.201592404","volume":"35","author":"GR Diaferia","year":"2016","unstructured":"Diaferia, G. R. et al. Dissection of transcriptional and Cis\u2010Regulatory control of differentiation in human pancreatic Cancer. EMBO J. 35, 595\u2013617. https:\/\/doi.org\/10.15252\/embj.201592404 (2016).","journal-title":"EMBO J."},{"key":"91875_CR102","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1161\/CIRCRESAHA.120.316738","volume":"128","author":"ID Kyriazis","year":"2021","unstructured":"Kyriazis, I. D. et al. KLF5 is induced by FOXO1 and causes oxidative stress and diabetic cardiomyopathy. Circ. Res. 128, 335\u2013357. https:\/\/doi.org\/10.1161\/CIRCRESAHA.120.316738 (2021).","journal-title":"Circ. Res."},{"key":"91875_CR103","doi-asserted-by":"publisher","unstructured":"Neuber, C. et al. The Pyrazolo[3,4-d]Pyrimidine-Based kinase inhibitor NVP-BHG712: effects of regioisomers on tumor growth, perfusion, and hypoxia in EphB4-Positive A375 melanoma xenografts. Molecules 25 https:\/\/doi.org\/10.3390\/molecules25215115 (2020).","DOI":"10.3390\/molecules25215115"},{"key":"91875_CR104","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s10456-010-9183-z","volume":"13","author":"GMB P","year":"2010","unstructured":"P., G. M. B., C., H. E. B., J., S. & M., B. P., I. The small molecule specific EphB4 kinase inhibitor NVP-BHG712 inhibits VEGF driven angiogenesis. Angiogenesis 13, 259\u2013267 (2010).","journal-title":"Angiogenesis"},{"key":"91875_CR105","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1038\/s42255-022-00634-5","volume":"4","author":"X Liu","year":"2022","unstructured":"Liu, X. et al. Insulin induces insulin receptor degradation in the liver through EphB4. Nat. Metab. 4, 1202\u20131213. https:\/\/doi.org\/10.1038\/s42255-022-00634-5 (2022).","journal-title":"Nat. Metab."},{"key":"91875_CR106","doi-asserted-by":"publisher","unstructured":"Wishart, D. S. et al. DrugBank: A knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 36 https:\/\/doi.org\/10.1093\/nar\/gkm958 (2008).","DOI":"10.1093\/nar\/gkm958"},{"key":"91875_CR107","doi-asserted-by":"publisher","first-page":"2920","DOI":"10.1111\/bcp.15833","volume":"89","author":"CY Chui","year":"2023","unstructured":"Chui, C. Y., Moes, D. J. A. R., Koolen, S. L. W., Swen, J. J. & Gelderblom, H. Pharmacokinetic profile of Irinotecan in patients with chronic kidney disease: two cases and literature review. Br. J. Clin. Pharmacol. 89, 2920\u20132925. https:\/\/doi.org\/10.1111\/bcp.15833 (2023).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"91875_CR108","doi-asserted-by":"publisher","unstructured":"Capello, M. et al. CES2 expression in pancreatic adenocarcinoma is predictive of response to Irinotecan and is associated with type 2 diabetes. JCO Precis Oncol. 426\u2013436. https:\/\/doi.org\/10.1200\/po.19.00330 (2020).","DOI":"10.1200\/po.19.00330"},{"key":"91875_CR109","doi-asserted-by":"publisher","unstructured":"Yarchoan, M. et al. Olaparib in combination with Irinotecan, cisplatin, and mitomycin C in patients with advanced pancreatic Cancer. Oncotarget 8 https:\/\/doi.org\/10.18632\/oncotarget.17237 (2017).","DOI":"10.18632\/oncotarget.17237"},{"key":"91875_CR110","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s00280-019-04025-8","volume":"85","author":"Z Wang","year":"2020","unstructured":"Wang, Z., Gao, J., Ohno, Y., Liu, H. & Xu, C. Rosiglitazone ameliorates senescence and promotes apoptosis in ovarian Cancer induced by Olaparib. Cancer Chemother. Pharmacol. 85, 273\u2013284. https:\/\/doi.org\/10.1007\/s00280-019-04025-8 (2020).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"91875_CR111","doi-asserted-by":"publisher","unstructured":"Oncologist, T. Kidney Cancer Research Summit Abstracts. Oncologist 2023, 28, S1\u2013S1, (2023). https:\/\/doi.org\/10.1093\/oncolo\/oyad216.001","DOI":"10.1093\/oncolo\/oyad216.001"},{"key":"91875_CR112","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s10637-005-4543-z","volume":"24","author":"J Vuky","year":"2006","unstructured":"Vuky, J. et al. Phase II trial of Imatinib (Gleevec\u00ae) in patients with metastatic renal cell carcinoma. Invest. New. Drugs. 24, 85\u201388. https:\/\/doi.org\/10.1007\/s10637-005-4543-z (2006).","journal-title":"Invest. New. Drugs"},{"key":"91875_CR113","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.ymthe.2022.11.004","volume":"31","author":"YH Shi","year":"2023","unstructured":"Shi, Y. H., Xu, Q. C., Zhu, Y. Q., Liu, Z. & De Imatinib facilitates gemcitabine sensitivity by targeting epigenetically activated PDGFC signaling in pancreatic Cancer. Mol. Ther. 31, 503\u2013516. https:\/\/doi.org\/10.1016\/j.ymthe.2022.11.004 (2023). ZhaoG.Y.Liu, Q.; Wang, X.Y.; Wang, J.Q.; Xu, X.; Su, Q.; et al.","journal-title":"Mol. Ther."},{"key":"91875_CR114","doi-asserted-by":"publisher","DOI":"10.21037\/sci.2018.02.02","author":"V Venkatesh","year":"2018","unstructured":"Venkatesh, V. et al. Target. Notch Signal. Pathw. Cancer Stem Cells doi:https:\/\/doi.org\/10.21037\/sci.2018.02.02. (2018).","journal-title":"Target. Notch Signal. Pathw. Cancer Stem Cells"},{"key":"91875_CR115","unstructured":"S030573721400125X."},{"key":"91875_CR116","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1007\/s12272-018-01108-7","volume":"42","author":"ES Cho","year":"2019","unstructured":"Cho, E. S., Kang, H. E., Kim, N. H. & Yook, J. I. Therapeutic implications of Cancer Epithelial-Mesenchymal transition (EMT). Arch. Pharm. Res. 42, 14\u201324. https:\/\/doi.org\/10.1007\/s12272-018-01108-7 (2019).","journal-title":"Arch. Pharm. Res."},{"key":"91875_CR117","doi-asserted-by":"publisher","unstructured":"Zheng, Y. et al. Insulin-like growth factor 1-Induced enolase 2 deacetylation by HDAC3 promotes metastasis of pancreatic Cancer. Signal. Transduct. Target. Ther. 5 https:\/\/doi.org\/10.1038\/s41392-020-0146-6 (2020).","DOI":"10.1038\/s41392-020-0146-6"},{"key":"91875_CR118","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/S1470-2045(15)70081-1","volume":"16","author":"M Fassnacht","year":"2015","unstructured":"Fassnacht, M. et al. Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: A Double-Blind, randomised, phase 3 study. Lancet Oncol. 16, 426\u2013435. https:\/\/doi.org\/10.1016\/S1470-2045(15)70081-1 (2015).","journal-title":"Lancet Oncol."},{"key":"91875_CR119","doi-asserted-by":"crossref","unstructured":"Xu, K. et al. Construction of five Disulfidptosis-Related LncRNA signature for predicting prognosis and immune activity in kidney renal clear cell carcinoma. (2023).","DOI":"10.21203\/rs.3.rs-2870664\/v1"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-91875-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-91875-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-91875-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,2]],"date-time":"2025-03-02T20:49:02Z","timestamp":1740948542000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-91875-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,2]]},"references-count":119,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["91875"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-91875-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,2]]},"assertion":[{"value":"30 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7363"}}